Trial Profile

A Phase I First-in-Human, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 09 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SIM 0609 (Primary)
Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Jiangsu Simcere Pharmaceutical

09 Dec 2025 New trial record
07 Nov 2025 According to Simcere Zaiming media release, company has announced that the first patient has been dosed in a Phase I clinical study for anti-tumor new drug candidate SIM0609 at Peking University Cancer Hospital.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com